<DOC>
	<DOCNO>NCT00853762</DOCNO>
	<brief_summary>This study ( 28851 ) long-term follow-up study subject enrol ATAMS study 28063 ( NCT00642902 ) . The aim study monitor safety tolerability atacicept administer 5 year subject relapse multiple sclerosis ( RMS ) . This extension study consist two part . Part A double blind Part B open label . During Part A , subject initially randomize atacicept continue receive atacicept dose randomize study 28063 ( ATAMS ) week subcutaneously ( skin ) . Subjects randomize placebo ATAMS receive atacicept 150 mg week subcutaneously Part A . Once result ATAMS available atacicept dose best benefit / risk ratio identify , subject switch dose continue extension study open-label ( Part B ) . Throughout study , subject investigator remain blinded respect initial part A treatment allocation/dose .</brief_summary>
	<brief_title>Atacicept Multiple Sclerosis Extension Study , Phase II</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Participation study 28063 . Completion Week 36 visit core study 28063 . Willingness ability comply study procedure duration study . Voluntary provision write informed consent ( include , USA , subject authorization Health Insurance Portability Accountability Act ( HIPAA ) ) , give studyrelated procedure part normal medical care understand subject may withdraw consent time without prejudice future medical care . Premature discontinuation core study 28063 . Subjects meet criterion list receive IMP study 28851 : Subjects eligible participation extension study 28851 meet criterion treat IMP undergo schedule visit , irrespective treatment . All subject must satisfy follow criterion Extension Study Day 1 ( D1EXT ; define first day dose extension study ) eligible treatment IMP : Eligibility participation extension study 28851 . For woman childbearing potential , negative urine pregnancy test eligibility assessment . Female subject childbearing potential must willing avoid pregnancy use adequate method contraception four ( 4 ) week first dose administer within extension study , study twelve ( 12 ) week last dose trial medication . Adequate contraception define two barrier method , one barrier method spermicide , intrauterine device , use combine oral female hormonal contraceptive ( definition request health authority locally amend core study 28063 ) . For purpose trial , woman childbearing potential define : `` All female subject puberty unless postmenopausal least two year surgically sterile '' ( For Germany Only : Female subject childbearing potential must willing avoid pregnancy use highly effective method contraception approximately four ( 4 ) week prior D1EXT , twelve ( 12 ) week last dose trial medication . This requirement apply surgically sterile subject subject postmenopausal least 2 year . Highly effective contraception define method combination method result low failure rate ( i.e . le ( &lt; ) 1 % per year ) use consistently correctly , implant , injectables , combine oral contraceptive , sexual abstinence , vasectomized partner , 2 barrier method , 1 barrier method spermicide ) Willingness ability comply study procedure duration study . To eligible treatment investigational medicinal product ( IMP ) study 28851 , subject must meet following criterion : Noneligibility participation extension study 28851 ( premature discontinuation core study 28063 ) . Major protocol violation noncompliance core study . Use prohibit immunomodulatory / immunosuppressive therapy Serum immunoglobulin G ( IgG ) level &lt; 3 gram per liter ( g/L ) subject receive atacicept core study , serum IgG level &lt; 6 g/L subject receive placebo core study ( protect blinding core study , IgG level communicate treat physician low extension study participation Week 36 assessment perform within core study complete ) . Any condition , include laboratory finding , opinion Investigator , constitute risk contraindication participation extension study , could interfere study objective , conduct evaluation . Known active clinically significant acute chronic infection , major episode infection require hospitalization treatment parenteral antiinfectives . Investigator judgement treatment subject atacicept extension study appropriate . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( AP ) level great ( &gt; ) 2.5 x upper limit normal ( ULN ) , total bilirubin &gt; 1.5 x ULN eligibility assessment . Clinically significant abnormality hematological test ( e.g . hemoglobin &lt; 100 g/L ( 6.21 millimoles per liter [ mmol/L ] ) , white blood cell &lt; 3 x 10^9 per liter ( /L ) , platelets &lt; 100 x 10^9/L ) eligibility assessment . Clinically significant abnormality electrocardiogram ( ECG ) perform eligibility assessment . Presence uncontrolled New York Health Association ( NYHA ) class 3 4 congestive heart failure Week 36 core study . Moderate severe renal impairment ( creatinine clearance &lt; 50 milliliter per minute ( mL/min ) accord CockcroftGault equation ) . Allergy hypersensitivity gadolinium ( Gd ) . Allergy hypersensitivity atacicept component formulate atacicept . Diagnosis family history CreutzfeldtJakob disease ( CJD ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>